Study of HS-10365 in people with and without liver problems
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how a drug called HS-10365 behaves in your body if you have a stable liver condition compared to people with healthy livers. It helps doctors understand whether the dose needs to be adjusted for people with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- If you have liver problems, they must be stable (not getting worse) for at least 2 months.
- You must not have severe heart problems or long QT syndrome.
- You need to avoid grapefruit and certain medications for at least 14 days before the study starts.
- If you have healthy liver function, you must not have had liver disease in the past.
- You must be willing to use effective birth control from the time you sign up until 6 months after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how the drug HS-10241 works in people with mild to moderate liver impairment compared to those with normal liver function. It aims to help doctors understand the right dose and safety in people with liver disease.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
This study tests a new drug called HS-20093 for people with limited-stage small cell lung cancer that has not spread and has already been treated with chemotherapy and radiation. The goal is to see if this drug helps keep the cancer from coming back, compared to just watching and waiting.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests an investigational drug, HS-10542, in healthy adults to see how it is processed by the body and to check for side effects. You must be willing to receive two vaccines before the study starts.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.